Our Team

Satish Vankayalapati

Founder, Chairman & CEO

Prior to founding Orvito, Satish Vankayalapati was a partner at McKinsey & Company, where he co-led key initiatives for Fortune 500 clients across the globe in the telecom, datacom, engineering and software services sectors. He successfully led pioneering efforts in next generation technologies, smart cities, and convergence.

Previously, Satish was a founding member of a telecom subsystem/components company that achieved a successful listing on the BSE.

Satish holds an MBA from the Kellogg School of Management, Northwestern University and a B.S. in Mechanical Engineering.

Mohan Vellanki

Founder, Chief Technology Officer & Head of Business Development

Mohan Vellanki brings over 14 years of experience in product sales, business development and engineering. Prior to founding Orvito, Mohan worked at Motorola in a variety of functions including Systems Architect, Program Manager and Technical Marketer. As a Technical Specialist at Motorola, he played a key role in launching nine different mobile phones and their variants.

Mohan also worked at Redpine Signmals, where he developed new product lines, corporate alliances and sales partners. Through his work, he delivered multi-million dollar revenue growth aross North America, Europe and Asia. In addition to his demonstrated expertise in delivering cutting edge technology innovation and driving technology roadmaps, Mohan is a proven leader who has overseen several integration initiatives that span operations in several countries, and managed multiple vendors and distribution channels.

He holds an MS in Telecommunications Engineering from Columbia University and an MBA from the Indian School of Business.

Rehan Atiq

Member of the Board

Rehan is the Founder, Chairman, CEO of Region Capital Partners. Prior to founding RCP, he co-founded a mid-income housing developer in South India. Rehan served as Vice-Chairman & Co-CEO of Capri Global Capital, the international arm of Capri Capital Partners (a $4B real estate asset management firm based in Chicago) from 2007-2009. In this role he led the team to sign over $2B of private equity deals with the Government of Saudi Arabia. He also served as an advisor to the Government of Qatar in developing the Qatar Financial Centre. He has been quoted and interviewed in several publications including CNBC to discuss developments in emerging markets. Rehan spent his earlier career as an Aerospace Engineer and an entrepreneur in USA. He holds an M.S. in Aerospace Engineering from Cornell University and an MBA from the Kellogg School of Management, Northwestern University.

Clementine Culot

Member of the Board

Clementine brings 10 years of consulting experience from McKinsey & Company, where she worked across multiple sectors with a particular focus on Marketing and Sales for business-to-business companies. Previously, Clementine worked for Agfa-Gevaert in Chile, where she supported sales strategy and planning for the medical imaging and IT division of Agfa-Gevaert Latin America.

Clementine holds a Master degree in Commercial Engineering from Universite Catholique de Louvain in Belgium. She currently resides in Singapore.

Dr. Javaid I. Sheikh

Member of the Board

Dr. Javaid Sheikh is currently the Dean of Weill Cornell Medicine-Qatar (WCM-Q), and is an internationally renowned medical executive and creative thought leader in global academic medicine. Professor Sheikh has pioneered innovative educational and research programs enabling WCM-Q to become widely acknowledged as a leading institution preparing "Global Physicians" for the 21 st century.

Prior to joining WCM-Q in 2007, Dean Sheikh built a distinguished career at the prestigious Stanford University School of Medicine in California as a Professor of Psychiatry and Behavioral Sciences, Associate Dean and Chairman of the Board of the Palo Alto Institute for Research and Education. Dr. Sheikh has been an angel investor for more than two decades in start-ups in the silicon valley and elsewhere and has served as a scientific advisor to several biomedical and pharmaceutical companies.